Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:ENGN

enGene Q3 2024 Earnings Report

enGene logo
$1.44 -0.06 (-3.69%)
As of 12:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

enGene EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.37
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q3 2024
Date
9/10/2024
Time
TAS
Conference Call Date
Tuesday, September 10, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

enGene's Q2 2026 earnings is estimated for Thursday, June 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, June 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

enGene's Q3 2024 Press ReleasePress Release
(8-K)
enGene's Q3 2024 Quarterly reportQuarterly report
(10-Q)

enGene Earnings Headlines

The Little Toyota Sports Car Engine That Gave Bigger Rivals A Run For Their Money
May 11 at 7:40 PM  |  msn.comhttps://www.msn.com/en-us/autos/enthusiasts/the-little-toyota-sports-car-engine-that-gave-bigger-rivals-a-run-for-their-money/ar-AA22UhOI
A 1.4L Chevy Spark Engine Doesn’t Sound Too Crazy Until You Put It in a Polaris
May 11 at 7:40 PM  |  msn.comhttps://www.msn.com/en-us/autos/research/a-14l-chevy-spark-engine-doesn-t-sound-too-crazy-until-you-put-it-in-a-polaris/ar-AA22QXTg
Your book attached
Bill Poulos is offering a temporary backdoor link that skips the order page for his Simple Options Trading For Beginners guide - normally $29.97 on his website. No cart, no checkout. The link goes straight to the download page at no cost. Once it expires, the full price applies.tc pixel
May 12 at 1:00 AM  |  Profits Run (Ad)
Pratt & Whitney clears key hurdle for XA103 engine for US’ next-gen fighter jet
May 11 at 7:40 PM  |  msn.comhttps://www.msn.com/en-us/news/technology/pratt-whitney-clears-key-hurdle-for-xa103-engine-for-us-next-gen-fighter-jet/ar-AA22Ulus
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
May 9 at 3:01 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4901996-engene-therapeutics-inc-engn-discusses-pivotal-cohort-data-from-legend-trial-of-detalimogene
Citizens downgrades enGene Therapeutics (ENGN)
May 9 at 9:16 AM  |  msn.comhttps://www.msn.com/en-us/health/other/citizens-downgrades-engene-therapeutics-engn/ar-AA22KjlX
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

View enGene Profile
Earnings Tools